This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Why Haemonetics is on investors’ radar today Haemonetics (HAE) is drawing attention after recent share performance that includes a month decline of about 3% and a past 3 months drop of roughly 24%, ...

In recent months, Haemonetics has reported a recovery in its Hospital division, supported by broader adoption of its FDA-approved NexSys PCS system with Persona Technology and the completed transition ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Haemonetics (NYSE:HAE) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

In recent years, much of Haemonetics’ focus has been on building out a portfolio of devices for interventional cardiology procedures. Its latest M&A move continues that trend. The Boston-based ...